Download PDF
Z Gastroenterol 2007; 45(2): 191-193
DOI: 10.1055/s-2007-962860
Übersicht

© Karl Demeter Verlag im Georg Thieme Verlag KG Stuttgart · New York

Neues aus der Cochrane Library: Behandlung der nicht alkoholischen Fettleber und Fettleberhepatitis

News from the Cochrane Library: Treatment of nonalcoholic Fatty Liver Disease and SteatohepatitisA. Timmer1
  • 1Deutsches Cochrane-Zentrum, Universitätsklinikum Freiburg
Further Information

Publication History

Publication Date:
15 February 2007 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Cochrane Library - Umbrella-Review - Metaanalyse - systematische Übersichtsarbeit - Nicht alkoholinduzierte Fettlebererkrankung - Nicht alkoholinduzierte Steatohepatitis

Key words

Cochrane Library - umbrella review - metaanalysis - systematic review - non-alcoholic fatty liver disease - non-alcoholic steato hepatitis

Literatur

  • 1 Angelico F, Burattin M, Alessandri C. et al . Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis (Review).  Cochrane Database Syst Rev. 2007 (1) CD 005 166
    PubMedGoogle Scholar
  • 2 Orlando R, Azzalini L, Orando S. et al . Bile acids for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis (Review).  Cochrane Database Syst Rev. 2007 (1) CD005160
    PubMedGoogle Scholar
  • 3 Lirussi F, Azzalini L, Orando S. et al . Antioxidant supplements for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis (Review).  Cochrane Database Syst Rev. 2007 (1) CD004996
    PubMedGoogle Scholar
  • 4 Lirussi F, Mastropasqua E, Orando S. et al . Probiotics for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis (Review).  Cochrane Database Syst Rev. 2007 (1) CD005165
    PubMedGoogle Scholar
  • 5 Sanyal A J. AGA technical review on nonalcoholic fatty liver disease.  Gastroenterology. 2002;  123 (5) 1705-1725
    CrossrefPubMedGoogle Scholar
  • 6 Kluwe J, Lohse A W. Therapieoptionen für die nicht-alkoholinduzierte Fettleber und Fettleberhepatitis.  Internist (Berl). 2005;  46 (12) 1324-1330
    CrossrefPubMedGoogle Scholar
  • 7 Siebler J, Galle P R. Treatment of nonalcoholic fatty liver disease.  World J Gastroenterol. 2006;  12 (14) 2161-2167
    PubMedGoogle Scholar
  • 8 Angulo P. Use of ursodeoxycholic acid in patients with liver disease.  Curr Gastroenterol Rep. 2002;  4 (1) 37-44
    PubMedGoogle Scholar
  • 9 Belfort R, Harrison S A, Brown K. et al . A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.  N Engl J Med. 2006;  355 (22) 2297-2307
    CrossrefPubMedGoogle Scholar
  • 10 Wang R T, Koretz R L, Yee H F. Weight reduction for non-alcoholic fatty liver (protocol).  Cochrane Database Syst Rev. 2002;  2002 (1) CD003619
    PubMedGoogle Scholar
  • 11 Higgins J P, Thompson S G. Quantifying heterogeneity in a meta-analysis.  Stat Med. 2002;  21 (11) 1539-1558
    PubMedGoogle Scholar

Antje Timmer

Deutsches Cochrane-Zentrum, Universitätsklinikum Freiburg, Institut für Medizinische Biometrie und Medizinische Informatik

Stefan-Meier-Str. 26

79104 Freiburg

Phone: ++49/7 61/2 03 67 15

Fax: ++49/7 61/2 03 67 12

Email: timmer@cochrane.de

      >